New Hope for Aging Eyes: Stem Cell Therapies to Combat Macular Degeneration
"Groundbreaking research explores how stem cell treatments could reverse vision loss from age-related macular degeneration, offering a new outlook for millions."
Age-related macular degeneration (AMD) significantly impairs central vision, affecting crucial daily activities, and isolating individuals. With millions affected globally, the advanced stages of AMD present a substantial challenge.
Current treatments for 'wet' AMD, which involve regular injections of anti-VEGF drugs, are not curative and place a significant burden on healthcare systems. Alarmingly, 'dry' AMD, which accounts for 90% of cases, currently has no effective treatments, highlighting a critical unmet need in an aging population.
However, researchers are exploring stem cell-based therapies aimed at replacing damaged retinal pigment epithelium (RPE) cells. This article examines these new therapies, their potential to restore vision, and the challenges that lie ahead in making them widely available.
AMD’s Global Impact
Macular degeneration affected about 196 million people worldwide as of 2020, according to the cited statistics page. It is described there as the leading cause of permanent impairment of reading and fine close-up vision in people over 65. The other listed statistics source provides no specific figures in its supplied summary, so no additional prevalence estimate can be verified from these materials.
Limits of Current AMD Treatment
The supplied review summaries describe current AMD therapies as having limitations, with a 2025 review specifically identifying limited efficacy of anti-VEGF treatment, particularly for dry AMD. A separate review characterizes AMD as a prevalent, complex disease that can lead to severe vision loss and presents stem cells as a potential way to replace lost retinal cell types. The available summaries do not specify particular standard-treatment regimens or quantify their limitations.
From Cell Therapy Research to Retinal Repair
A review of retinal degeneration cell therapies focuses on transplantation of retinal pigment epithelium (RPE) and photoreceptor cells derived from pluripotent stem cells. This identifies cell replacement as a foundational strategy for retinal repair. The other supplied source describes stem-cell treatment as an innovative, developing approach but gives no named milestone or date.
Revolutionizing Treatment with RPE-Based Therapies
Given the critical role of RPE cells in AMD, scientists have long considered RPE replacement a promising treatment strategy. Early attempts involved surgical transplantation of autologous RPE, which showed some success but were technically challenging and carried significant risks. Now, the focus has shifted to using exogenous RPE cells derived from stem cells.
- Ocata Therapeutics (California): Pioneered the transplantation of human embryonic stem cell-derived RPE cells into patients with advanced dry AMD and Stargardt's disease. Early results showed no evidence of rejection or tumor formation, suggesting the potential of HESC as a safe cell source.
- Riken Centre (Japan): Reported transplanting induced pluripotent stem cell (IPSC)-derived RPE into an AMD patient. This was the first IPSC trial worldwide, using cells derived from the patient's own skin, potentially reducing the risk of immune rejection.
- London Project to Cure Blindness: Transplanted HESC-derived RPE cells as a monolayer patch on a coated polymer sheet into a patient with recently diagnosed wet AMD. This approach aims to replace Bruch's membrane and support the remaining retinal structure.
Cell-Transplant Programs and Cell Storage
A systematic review by Ramsden et al. identified three teams conducting cell transplants: Ocata in California, the Riken Centre in Japan in collaboration with Kobe City General Hospital, and the London Project to Cure Blindness. At the time described, the review reported one patient for the Riken collaboration and one patient in the London Project, whose case involved wet AMD; its snippet adds that each had progressed to at least two patients, with five candidates enrolled for the Riken collaboration and another wet-AMD patient for the London Project. Separately, a 2018 cell-storage study found that a medium supplemented with sericin, adenosine, L-ascorbic acid, and allopurinol produced the highest reported viability—98.6 ± 0.5%—after three days of storage.
Promise with Clinical Questions Still Open
The supplied review describes stem cells as promising because they may replace lost host retinal cells or provide trophic support that promotes the survival of existing retinal cells. A 2022 review says stem-cell therapy for retinal degeneration is moving from research toward clinical study worldwide, and that the safety of induced pluripotent stem-cell-derived RPE transplantation has begun to be clarified. These summaries do not report specific failures or establish long-term effectiveness, so they support cautious interest rather than a conclusion that the approach is proven.
Different Needs in Wet and Dry AMD
AMD has two primary forms: neovascular (wet) and non-neovascular (dry), according to the 2025 review. That review says current anti-VEGF treatments have limited efficacy, particularly for dry AMD, motivating the search for alternatives. BrightFocus describes cell therapy, including stem cells and stem-cell-derived treatments, as an area researchers are exploring to repair or replace damaged retinal cells in macular degeneration and geographic atrophy, with delivery methods and potential risks under discussion.
The Future of AMD Treatment: Challenges and Opportunities
While these initial clinical trials are promising, translating stem cell therapies into widespread treatments for AMD faces several challenges. These include navigating complex regulatory pathways, scaling up cell production to meet global demand, and managing the high costs associated with advanced therapy medicinal products (ATMPs).
Early Trial Results in Advanced Dry AMD
A first-of-its-kind trial is testing adult stem-cell transplants for advanced dry macular degeneration, according to the two supplied reports. Both say early results suggest the treatment is safe and can significantly improve vision, including for severely affected patients. These are preliminary reports, so they point to a research direction rather than establish how well the treatment will work more broadly.
Stem Cells Across Eye Diseases
A 2024 review places AMD within a wider group of degenerative eye disorders that includes glaucoma and cataracts, which it describes as prevalent causes of blindness and visual impairment worldwide. It also discusses limbal stem-cell deficiency, dry eye disease, and retinitis pigmentosa, conditions associated with ocular discomfort or impaired visual function. This broader scope highlights that regenerative eye research addresses multiple disorders, not AMD alone.
Stratified medicine, which involves understanding disease subtypes and predicting treatment responses, could also play a key role. In the future, using cells differentiated to photoreceptors in addition to an RPE transplant could also aid patients with photoreceptor loss.
Despite these challenges, the commencement of clinical trials for AMD represents a major milestone in regenerative medicine. With continued research, technological advancements, and the dedicated involvement of patients, stem cell therapies hold immense potential to transform the treatment of AMD and restore sight to millions.